Anticonvulsant Pharmacokinetics Dennis Mungall, Pharm.D. Director, Virtual Education, NTPD Associate Professor Pharmacy Practice Ohio State University.

Slides:



Advertisements
Similar presentations
Instant Clinical Pharmacology E.J. Begg
Advertisements

First, zero, pseudo-zero order elimination Clearance
Pharmacokinetics as a Tool
Prepared by: Raed A. AL-Mohiza Directed by: Dr. Hesham Abo-Audah
Pharmacotherapy in the Elderly Judy Wong
Pharmacokinetics Questions
Nonlinear pharmacokinetics
Dosage Adjustments for Aminoglycosides in Obese Patients Dennis Mungall, Pharm.D. Associate Professor, Pharmacy Practice Director, NTPD OSU,College of.
Laplace transformation
Practical Pharmacokinetics
Practical Pharmacokinetics September 11, 2007 Frank F. Vincenzi.
Dose Adjustment in Renal and Hepatic Disease
INTRAVENOUS INFUSION.
Pharmacology Department
CLEARANCE (CL) describes the efficiency of irreversible elimination of a drug from the body by excretion of unchanged drug. Metabolic conversion of the.
PHARMACOKINETICS 1. Fate of drugs in the body 1.1 absorption
Nonlinear Pharmacokinetics
Nonlinear Pharmacokinetics Prepared By, Jahanvi H. Patel Roll No:09MPH103 Dept: Pharmaceutical Technology & Biopharmaceutics Guided By: Dhaivat C. Parikh.
Pharmacokinetics Introduction
Valproic Acid Software and Presentation by: Ted, Rob, Jeff, Cassie, Tristan, Korin, Ron, Gabe, Matt, Judith, Lindsay.
PLASMA HALF LIFE ( t 1/2 ).  Minimum Effective Concentration (MEC): The plasma drug concentration below which a patient’s response is too small for clinical.
Drug Administration Pharmacokinetic Phase (Time course of ADME processes) Absorption Distribution Pharmaceutical Phase Disintegration of the Dosage Form.
Special Populations: Pediatrics Arthur G. Roberts.
Multiple dosing: intravenous bolus administration
1 Single-dose kinetics Plasma [Drug] curve Upon administration [drug] plasma reaches a max Then begins to decline as the Drug is eliminated Cp max = max.
CLINICAL PHARMACOKINETICS OF LIDOCAINE
Clinical Pharmacokinetics of Carbamazepine
1. Fate of drugs in the body 1.1 absorption 1.2 distribution - volume of distribution 1.3 elimination - clearance 2. The half-life and its uses 3. Repeated.
Continuous intravenous infusion (one-compartment model)
INTRODUCTION CLINICAL PHARMACOKINETICS
BIOPHARMACEUTICS.
Principles of pharmacokinetics Prof. Kršiak Department of Pharmacology, Third Faculty of Medicine, Charles University in Prague Cycle II, Subject: General.
TDM Therapeutic Drug Monitoring
Clinical Pharmacokinetics of Phenobarbital
Nonlinear Pharmacokinetics
© Paradigm Publishing, Inc.1 Chapter 2 Basic Concepts of Pharmacology.
Prof. Dr. Henny Lucida, Apt
Pharmacokinetics of Vancomycin in Adult Oncology Patients Hadeel Al-Kofide MS.c; Iman Zaghloul PhD; and Lamya Al-Naim PharmD Department of Clinical Pharmacy,
Clinical Pharmacokinetics of PHENYTOIN & OTHER ANTIEPILEPTICS
Clinical Pharmacokinetic Equations and Calculations
Case 9 Amikacin in an elderly CKD patient Block 9 : Divine Ramos, Remonte, Reyes, Rivera A, Rivera K, Rivera M, Rogelio, Sagayaga, Santiago, See, Siy,
Foundation Knowledge and Skills
Pharmacokinetics: Digoxin Allie Punke
Osphena® (ospemifene) Stefanie L Drahuschak University of Pittsburgh PharmD Candidate 2014.
ALLIE PUNKE PHARMCOKINETICS. PHENYTOIN THE BASICS What is the volume of distribution: Regular floor patient: L/kg Critically ill patient: 0.8.
Pharmacokinetics 3rd Lecture
Anticonvulsants: Phenytoin
Pharmacokinetics: Pediatrics
The aminoglycoside antibiotics
Pharmacokinetics Tutoring
Pharmacokinetic Modeling (describing what happens)
PHARMACOKINETICS Allie punke
Pharmacokinetics.
Pharmacokinetics Tutoring
Dosing Regimen Concepts: 2-C, MM, Individualization principles
Anticonvulsants: Valproic acid
Pharmacokinetics: Pediatrics
Pharmacokinetics: Theophylline
Pharmcokinetics Allie punke.
Clinical Pharmacokinetics
Pharmcokinetics Allie punke.
Pharmacokinetics and Factors of Individual Variation
Clinical Pharmacokinetics
Selected Bioavailability and Pharmacokinetic Calculations
1 Concentration-time curve
Therapeutic Drug Monitoring chapter 1 part 1
Clinical Pharmacokinetics
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
Drug Therapy in Pediatric Patients
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
Presentation transcript:

Anticonvulsant Pharmacokinetics Dennis Mungall, Pharm.D. Director, Virtual Education, NTPD Associate Professor Pharmacy Practice Ohio State University College of Pharmacy

Absorption of Phenytoin Phenytoin sodium is 92% phenytoin The time to peak is 3-12 hours after single dose of a capsule or tablet Dilantin Kapseals are the only formulation that has absorption characteristics necessary for once daily dosing Oral absorption fo Dilantin approaches 100%

Oral preparations of Phenytoin

Time to Peak Cp Dose (mg) Peak Time ( hrs)

Parenteral Administration of Phenytoin Gugler R et al. Clin Pharmac.Ther 1976;

Distribution of Phenytoin Following IV phenytoin distribution to tissues occurs in minutes Distribution to the brain is very rapid The mean volume of distribution is comparable to total body water: Liters/kg. Phenytoin binds primarily to albumin, with approximately 10 percent of the drug normally unbound.

Conditions that lead to decreased protein binding of Phenytoin Decreased In serum Albumin Burns Hepatic cirrhosis Nephrotic syndrome Pregnancy Cystic Fibrosis Decreased in affinity of binding to albumin Renal Failure Jaundice Other medications

Adjustment of Total Phenytoin concentration for Albumin Cnormal = Cobserved/(0.2*alb+0.1)

Metabolism Elimination of phenytoin occurs primarily by biotransformation to inactive hydroxylated metabolites. The process of phenytoin elimination is saturable Thus, increases in dose lead to disproportionate increases in phenytoin concentration

Variation in Phenytoin Dose/cp Lund L. Bilogical Effects of Drugs. University Park Press 1972;227-39

Demonstration of Dose/CP nonlinearity for Phenytoin Richens A., Dunlop A. Lancet 1975;2:247-48

Steady State Concentration Vmax= maximum rate of phenytoin metabolism in mg/day Km: the concentration at which the rate of metabolism is half maximal ( mg/liter Css= Km-Dose(day)/Vmax-Dose(day)

Saturation Pathway for Phenytoin

Time to steady state based on dosing rate

Time to 90% of SS as a function of Vmax and Km

Equation for Time to 90% SS T90% =(Km*Vd)/(Vm-Dose) * (2.3*Vm –0.9*Dose)

Conditions Affection Phenytoin Condition or Disease Example Vmax increasedEnzyme inductionConcurrent phenobarb/Carbaz epine Vmax decreasedCirrhosisDecreased enzyme activity Km increasedCompetitive Inhibition Cimetidine or Chloramphenicol Km decreasedDecrease ProteinBinding Dec. albumin or displacers:Valproi c acid

Clinical Response and Side Effects Kutt H et al. Arch Neurol 1964; 11:642-48

Estimating the Loading Dose of Phenytoin LD= Vd (C desired – C observed)/S*F Where: Vd = volume of distribution ( 0.65L/kg) S=salt factor ( 0.92) F= fraction absorbed ( 1 ) Cdesired=10 to 20 mg/L Cobserved: if the patient is on phenytoin already and has a level prior to therapy

Estimating Maintenance Dose Mean Km for adults: 5.8 mg/L ( ) and 5.3 mg/l for children Mean Vmax for adults:8mg/kg/day, children 12 mg/kg/day Dose/day= Vmax*Css/Km+Css

Estimating Maintenance Dose Based on one SS Phenytoin CP Vozeh S et al. J Pharmacokinet Biopharm 1981;9:131-46

Estimation of Dose based on two SS Phenytoin CP:Mullen Method Mullen RW. Clin Pharm Ther 1978;23:228-32

Estimation of Dose based on two SS Phenytoin CP:Ludden Method Ludden TM et al. Clin Pharm Ther 1977;21:287-93

Case Study #1 Mr SG is a 58 y/o, 72 inch, 70 kg male, seen recently with symptoms of a lower Respiratory infection. At this time he had a lesion noted on his Chest X-ray. A lung biopsy revealed a carcinoma with metastasis to The head, demonstrated via a CT scan. His albumin was 4 gm/l and serum creatinine 1.0.Phenytoin therapy was initiated prohylactically at a dosage of 400 mg daily. Two weeksLater the patient had a grand mal seizure and the phenytoin Cp was5 mg/l. The dosage was increased to 500 mg qd and 3 weeks laterThe phenytoin concentration was 7 mg/l.

Case # 1: Questions Using the Ludden method graph and estimate the Vmax and Km for this patient. Using this information, estimate a dose necessary to achieve a phenytoin concentration of 15 mg/l Given the Vmax and Km estimate the timeto 90% of steady state Estimate a Loading dose to achieve 15mg/l now.

Case 1: Using DrugCalc Using drugcalc, input the patient history, dosing history, and phenytoin history and model this See how Vmax and Km compare with the Ludden method.

Case 1 : Answers to Ludden Method DoseCpDose/CP

Ludden Example Y intercept=1225mg/day= Vmax Slope=11.6mg/l= Km Dose/day=Vmax xCp/Km+cp Dose/day=1225x15/ Dose/day= 690mg phenytoin acid Dose/day=750 mg phenytoin sodium

Case 1 : Using Drugcalc Input the patient dosage/cp history and estimate Vmax and Km Using the Dosage calculator, estimate the dose to achieve a phenytoin concentration of 15 mg/L

Screen # 1 : Input the name/age After inputing the name and age click on accept

Choose phenytoin

Select Edit Demographics

Enter in the height, weight, serum albumin and serum creatinine When completed, click on accept

Select inpatient dosing

Insert Dose/Cp history Using the shortcut for multiple doses, 14s indicating 2 weeks, 21 s Indicating 3 weeks. D is for data ( concentration). ( s for sustained release) Click on add after entering each line. When complete click on accept

Choose Predict to Model : Select Parameters

Review the Vmax, Km, Vd Click on done when finished

Predicting SS dose Using the new vmax and Km and the equation for dose, reestimate, by hand the dose of phenytoin necessary to achieve a ss concentration of 15 mg/l